Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Cannon TL, Rothe M, Mangat PK, Garrett-Mayer E, Chiu VK, Hwang J, Vijayvergia N, Alese OB, Dib EG, Duvivier HL, Klute KA, Sahai V, Ahn ER, Bedano P, Behl D, Sinclair S, Thota R, Urba WJ, Yang ES, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Cannon TL, et al. Among authors: sahai v. J Clin Oncol. 2024 May 15:JCO2302078. doi: 10.1200/JCO.23.02078. Online ahead of print. J Clin Oncol. 2024. PMID: 38748939
Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Sahai V, Rothe M, Mangat PK, Garrett-Mayer E, Suhag V, Dib EG, Mehmi I, Kadakia KC, Pisick E, Duvivier HL, Le P, Li R, Michelin DP, Wilcox RE, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Sahai V, et al. JCO Precis Oncol. 2024 Apr;8:e2300527. doi: 10.1200/PO.23.00527. JCO Precis Oncol. 2024. PMID: 38603652
Targeting PIKfyve-driven lipid homeostasis as a metabolic vulnerability in pancreatic cancer.
Cheng C, Hu J, Mannan R, Bhattacharyya R, Rossiter NJ, Magnuson B, Wisniewski JP, Zheng Y, Xiao L, Li C, Awad D, He T, Bao Y, Zhang Y, Cao X, Wang Z, Mehra R, Morlacchi P, Sahai V, di Magliano MP, Shah YM, Ding K, Qiao Y, Lyssiotis CA, Chinnaiyan AM. Cheng C, et al. Among authors: sahai v. bioRxiv [Preprint]. 2024 Mar 20:2024.03.18.585580. doi: 10.1101/2024.03.18.585580. bioRxiv. 2024. PMID: 38562800 Free PMC article. Preprint.
A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma.
Enzler T, Nguyen A, Misleh J, Cline VJ, Johns M, Shumway N, Paulson S, Siegel R, Larson T, Messersmith W, Richards D, Chaves J, Pierce E, Zalupski M, Sahai V, Orr D, Ruste SA, Haun A, Kawabe T. Enzler T, et al. Among authors: sahai v. Eur J Cancer. 2024 Apr;201:113950. doi: 10.1016/j.ejca.2024.113950. Epub 2024 Feb 22. Eur J Cancer. 2024. PMID: 38422585 Free article. Clinical Trial.
Potentiating the radiation-induced type I interferon antitumoral immune response by ATM inhibition in pancreatic cancer.
Zhang Q, Jiang L, Wang W, Huber AK, Valvo VM, Jungles KM, Holcomb EA, Pearson AN, The S, Wang Z, Parsels LA, Parsels JD, Wahl DR, Rao A, Sahai V, Lawrence TS, Green MD, Morgan MA. Zhang Q, et al. Among authors: sahai v. JCI Insight. 2024 Feb 20;9(6):e168824. doi: 10.1172/jci.insight.168824. JCI Insight. 2024. PMID: 38376927 Free PMC article.
152 results